1. Overcoming barriers that inhibit proper treatment of anemia
R. Agarwal 
Kidney International 
Volume 69, Pages S9-S12 (May 2006)
DOI: /sj.ki
Copyright © 2006 International Society of Nephrology Terms and Conditions

2. Figure 1
Relative benefits and risks of EPO and i.v. iron therapy. NO=nitric oxide; HTN=hypertension; PDGF=platelet-derived growth factor; VSMC=vascular smooth muscle cells.1
Kidney International  , S9-S12DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

3. Figure 2
Blood pressure in rats with chronic renal failure (CRF) treated with either placebo, EPO, or EPO coupled with dietary iron deficiency (Fe def), 4 weeks after nephrectomy. The EPO-treated groups showed significant rise in blood pressure compared with the placebo-treated groups. Arrow indicates beginning of EPO or placebo treatment. Reprinted with permission from Am J Physiol. 1996; 271: E113–E122.22
Kidney International  , S9-S12DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions